BioCentury on BioBusiness,
Product Discovery & Development
Why doctors expect a slow start for Biogen Idec's rFVIIIFc in hemophilia A
Factors in hemophilia uptake
Monday, November 12, 2012
Physicians say last month's Phase III data for Biogen
Idec Inc.'s rFVIIIFc could motivate about 15% of hemophilia A patients
to switch treatments. Getting to a larger population may have to wait for
longer-term data expected late next year.
On Oct. 31, Biogen Idec and partner Swedish
Orphan Biovitrum AB reported data from the Phase III A-LONG trial
showing that two prophylaxis regimens with rFVIIIFc met the primary endpoint of
reducing annualized bleeding rates by 50% or more compared to on-demand
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]